Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01540721 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend
A Phase 1 study of Healthy Subjects, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01540721: Completed Phase 1 study of Healthy Subjects, sponsored by GlaxoSmithKline.
NCT01540721 is a Phase 1 study of Healthy Subjects that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01540721, a Phase 1 study of Healthy Subjects, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the pharmacokinetic profiles of experimental formulations of paracetamol.
Conditions Studied
Interventions
- DRUG Experimental paracetamol formulation
- DRUG Marketed paracetamol
Study Locations (1)
Nebraska
- MDS Pharma Services NEBRASKA - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
What the finished NCT01540721 record still lists
NCT01540721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Experimental paracetamol formulation is the first listed.
NCT01540721 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT01540721 about?
NCT01540721 is a clinical study titled "Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend". This study will evaluate the pharmacokinetic profiles of experimental formulations of paracetamol.
What is the current status of trial NCT01540721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-12. Estimated completion is 2009-12.
What conditions does trial NCT01540721 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT01540721?
The interventions under investigation include: Experimental paracetamol formulation (DRUG), Marketed paracetamol (DRUG).
Who is sponsoring clinical trial NCT01540721?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01540721 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01540721's enrollment target sits among peer trials
28 42nd of 69 higher than 26 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia